Newsroom

BioReference team is now able to provide the entire OvaSuite portfolio to healthcare providers in New York and New Jersey AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health…

Management to Announce Earnings Results and hold a call at 8:30 am ET AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the…

Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company’s development pipeline AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical…

Dear Shareholder, Yesterday, it was my honor to share news of an exciting development that we believe will shape Aspira Women’s Health for many years to come. We have been selected by the Advanced Research Projects Agency for Health (ARPA-H)…

SUMMARY: The addition of miRNA and metadata to Aspira’s existing protein assay shows promising improvements in both sensitivity and specificity for early-stage ovarian cancer in women with an adnexal mass AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) — Aspira Women’s…

AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women’s Health…

SUMMARY: The innovative new tool will be made available for integration into Electronic Medical Records at over 300 clinical sites serving 2,500 clinical users AUSTIN, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a…